CERAMENTTM|G and V in the Management of Hip and Knee Arthroplasty Revisions (Revision Arthroplasty Italy)

NCT ID: NCT03389646

Last Updated: 2018-01-03

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE4
• Total Enrollment: 135 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-09-27
• Study Completion Date: 2019-09-27

Brief Summary

Open-label, multicentre, prospective cohort, observational clinical trial with a retrospective control group to evaluate the effectiveness and safety of CERAMENTTM| G or V used for filling of bone defects in the tibia and / or femur shaft and/or acetabulum in patients scheduled for two-stage hip or knee prosthesis re-implantation for PJI or aseptic loosening.

The results will be compared to a cohort of patients, which have been treated before the introduction of CERAMENTTM|G or V for the same indication.

Due to the observational character of the study, there will be no patient randomization and the clinicians in the study will remain entirely free to decide on the treatment of the patients according to established clinical practice.

Only patients for whom therapeutic strategy for the use of the product for filling bone defects is already planned according to local clinical practice, at the time of informed consent form signature, will be enrolled in this study. Thus, the decision for the choice of the surgical treatment, will not be influenced by the inclusion of the patient in this study.

Conditions

Hip Prosthesis Infection; Knee Prosthesis Infection

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

Treated with Device: Including sham

Treated with CERAMENTTM\|G or V for filling of bone defects in the tibia and/or femur and/or the acetabulum.

Group Type: ACTIVE_COMPARATOR

CERAMENT G V

Intervention Type: DEVICE

During the removal of hip and knee prostheses usually bone defects occur at the intramedullary canal of the tibia and or / femur and /or acetabulum. These bone defects are filled with CERAMENTTM\|G or V during the re-implantation of the cementless or hybrid revision THA or TKA. CERAMENTTM\|G or V can be directly injected into the intramedullary canal or bone defect at the acetabulum. Alternatively and preferably, the surface of the prostheses shafts can be used to transfer CERAMENTTM\|G or V into the bone defects. For information of handling and mixing please see the attached instructions for use (IFU).

Control

Control without CERAMENT device

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

CERAMENT G V

During the removal of hip and knee prostheses usually bone defects occur at the intramedullary canal of the tibia and or / femur and /or acetabulum. These bone defects are filled with CERAMENTTM\|G or V during the re-implantation of the cementless or hybrid revision THA or TKA. CERAMENTTM\|G or V can be directly injected into the intramedullary canal or bone defect at the acetabulum. Alternatively and preferably, the surface of the prostheses shafts can be used to transfer CERAMENTTM\|G or V into the bone defects. For information of handling and mixing please see the attached instructions for use (IFU).

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Written informed consent obtained prior to any study related procedure.

2. Male or female age ≥ 18 and ≤ 85 years.

3. Patients diagnosed with aseptic prosthetic loosening and scheduled for a one-stage hip or knee cementless or hybrid revision prosthesis implantation

4. Patients with an interval spacer and scheduled for hip or knee cementless or hybrid revision prosthesis implantation.

5. For those patients with an interval spacer, previous infection caused by microorganism(s) sensitive to gentamicin or vancomycin.

6. Able (in the Investigators opinion) and willing to comply with all study requirements

Exclusion Criteria

1. Unable to give written informed consent.

2. Medically unfit for operative intervention.

3. Soft-tissue defects that prevent direct skin closure at revision surgery.

4. Females who are pregnant or lactating.

5. Females of child bearing potential and not taking adequate contraceptive precautions are excluded from the trial. Females of child bearing potential taking acceptable contraceptive precautions may be included.

6. Known allergy to gentamicin or vancomycin (or related antibiotics).

7. Patients with previous nephro- or ototoxicity events due to aminoglycoside and/or vancomycin (or glycopeptides) use.

8. Presence of relevant contraindications as described in the EU CE mark Instructions for Use (IFU).

9. Myasthenia gravis.

10. Need of a fully cemented joint prosthesis.

11. Psychiatric or neurological disorders.

12. Active infection at the site of surgery as diagnosed by clinical and/or laboratory and/or imaging investigations.

-

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

CARLO L ROMANO, MD

Role: PRINCIPAL_INVESTIGATOR

IRCCS GALEAZZI

Locations

Irccs Galeazzi

Milan, , Italy

Site Status: RECRUITING

Countries

Italy

Central Contacts

CARLO L ROMANO, MD

Role: CONTACT

carlo.romano@grupposandonato.it

+39026621441 ext. 907

NICOLA LOGOLUSO, MD

Role: CONTACT

nicola.logoluso@gmail.com

+39026621441 ext. 903

Facility Contacts

CARLO L ROMANO, MD

Role: primary

carlo.romano@grupposandonato.it

+39026621441 ext. 907

Other Identifiers

RAI2017

Identifier Type: -

Identifier Source: org_study_id